In re: Criminal Prosecution of Corporate Officers for Off-Label Promotion
- Case Date: 10/26/2010
- Project Name: Criminalization of Free Enterprise - Business Civil Liberties Program
On October 26, 2010, WLF called on the Food and Drug Administration to abandon its announced plans to seek increased criminal prosecution of company executives for promotional activities in instances where the executives never participated in, encouraged, or had knowledge of the alleged violations. WLF expressed its concerns in a letter to Eric Blumberg, Deputy Chief for Litigation in the FDAís Office of Chief Counsel, in response to recent comments Blumberg made calling for increased criminal prosecution of executive officers in pharmaceutical companies. WLF cautioned that increased criminal prosecution of company executives for promotional activities has the potential to adversely affect the nationís healthcare delivery system by providing industry executives little incentive to continue working in the pharmaceutical sector.
|Awaiting FDA response.|
More Information and Downloads:
10/26/2010: Download the Letter